Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Termination of Business Transfer Agreement Disclosure under Regulation 30 of SEBI Listing Regulations'.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.4 pts less than Nifty Microcap 250 and 7.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals has mutually terminated its Business Transfer Agreement to acquire Resilient Cosme-Ceuticals Private Limited, including its brands and trademarks. The termination, announced on May 6, 2025, is because certain conditions precedent required to close the deal could not be fulfilled. The original announcement for the proposed acquisition was made on February 21, 2025, with an expected closure within 45 days. The company has stated that the cancellation has no material financial or other impact.
The cancelled deal is unlikely to materially affect the stock price or shareholder value, as the company itself confirms no material financial impact. Investors should note that Jagsonpal's growth plans via this acquisition will not materialize, but existing operations remain unaffected.